J&J expands COVID-19 vaccine trial to include adolescents

April 5, 2021 – Johnson & Johnson (J&J) (New Brunswick, NJ) is expanding its coronavirus vaccine trials to include adolescents 12 to 17 years old. The phase 2a trial began in September 2020 and was initially designed to study single-dose and two-dose regimens of the vaccines in healthy adults aged 18 to 55 years old, and adults 65 years and older.

The vaccine will initially be tested in a small number of adolescents aged 16 to 17 years old. Following initial data review, the study will be expanded to a larger group of adolescents.

Learn More